The firm brings unique experience to tracking, assessing and explaining regulatory and reimbursement policy that affect the biopharmaceutical industry. The company’s goal is to advance mutual understanding among policymakers, business executives and the investment community, in the belief that a deeper understanding of policy leads to better business, and a deeper understanding of business leads to better policy.
Member Sign In:
- Payors Demand Dialogue On Pricing, But May Be Talking At Cross Purposes With Pharma; CMS Not A Threat Dec. 18, 2014
- Advisory Committee Trends: Panels Voted “Yes” 60% of the Time in 2014, 71% for New Molecular Entities Dec. 18, 2014
- E-labeling Proposed Rule Eliminates Paper Prescribing Information in Most Cases in Favor of FDA Online Repository Dec. 17, 2014
See More Research Notes